Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized,Double-Blind,Controlled Trial

Abstract

Spanish

French

Background:

The management of patients who are receiving warfarin therapy and have musculoskeletal problems that require treatment with a nonsteroidal antiinflammatory drug (NSAID) is problematic because NSAID use may increase the risk for bleeding. Cyclooxygenase-2 selective NSAIDs such as celecoxib may be less likely to promote gastrointestinal bleeding; however, there are concerns that they could potentiate the anticoagulation effect of warfarin.

Objective:

To determine whether celecoxib potentiates the anticoagulant effect of warfarin, as measured by the international normalized ratio (INR).

Methods:

We performed a randomized, controlled, crossover trial to assess the effect on INR of celecoxib versus codeine (control treatment) in 15 patients who were receiving warfarin therapy and required analgesic treatment for osteoarthritis. During Phase 1 of the study, patients were randomly allocated to receive celecoxib 200 mg/day or codeine phosphate 7–15 mg 3–4 times daily for 5 weeks. During Phase 2 of the study, patients stopped the first study medication and started the other study medication; there was no drug-free interval between phases. Weekly INR testing was performed during the 10 week study period. Adopting the intent-to-treat principle, we used generalized estimating equations to analyze the data.

Results:

There was no significant difference in the mean INR values during each 5 week treatment period when patients received either celecoxib or codeine. There was, therefore, insufficient evidence to reject the hypothesis that these 2 treatments had an equal effect on the INR (mean difference [95% CI] 0.10 [-0.04 to 0.24]; p=0.16) based on mean imputation. This finding was confirmed after we repeated the analysis with multiple imputations (mean difference [95% CI] 0.093 [-0.16 to 0.35]; p = 0.47).

Conclusions:

Our results suggest that treatment with celecoxib does not potentiate the INR when taken with warfarin. Larger randomized trials are warranted to address the effects of coadministered warfarin and celecoxib on clinical outcomes.

Keywords

anticoagulant effect celecoxib warfarin

Get full access to this article

View all access options for this article.

References

American Heart Association. Heart disease and stroke statistics: 2004 update. Dallas: American Heart Association, 2003.

Wolf

Abbott

Kannel

. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561–4.

Buckwalter

Saltzman

Brown

. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;427(suppl):S6–15.

Bagge

Bjelle

Eden

Svanborg

. A longitudinal study of the occurrence of joint complaints in elderly people. Age Ageing 1992;21:160–7.

Shorr

Ray

Daugherty

Griffin

. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665–70.

Schnitzer

. Non-NSAID pharmacologic treatment options for the management of chronic pain. Am J Med 1998;105(suppl 1-B):45S–52S.

Hylek

Heiman

Skates

Sheehan

Singer

. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657–62.

Silverstein

Faich

Goldstein

. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–55.

Simon

Weaver

Graham

. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921–8.

10.

Singh

Fort

Goldstein

. SUCCESS-I investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006;119:255–66.

11.

Schaefer

Plowman

Morreale

Egan

. Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm 2003;60:1319–23.

12.

Miners

Birkett

. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525–38.

13.

Linder

Monkemuller

Davis

Wilcox

. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. South Med J 2000;93:930–2.

14.

Mersfelder

Stewart

. Warfarin and celecoxib interaction. Ann Pharmacother 2000;34:325–7. DOI 10.1345/aph.19246

15.

Stading

Skrabal

Faulkner

. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001;58:2076–80.

16.

Haase

Rojas-Fernandez

Lane

Frank

. Potential interaction between celecoxib and warfarin (letter). Ann Pharmacother 2000;34:666–7. DOI 10.1345/aph.19324

17.

Manek

. Medical management of osteoarthritis. Mayo Clin Proc 2001;76:533–9.

18.

Tyndale

Droll

Sellers

. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997;5:375–9.

19.

Zeger

Liang

Albert

. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049–60.

20.

Little

RJA

Rubin

. Statistical analysis with missing data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc., 2002.

21.

Palareti

Leali

Coccheri

. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Study on complications or oral anticoagulant therapy. Lancet 1996;348:423–8.

22.

Hylek

Chang

. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019–26.

23.

Karim

Tolbert

Piergies

. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol 2000;40:655–63.

24.

Ryder

Benjamin

. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999;84:131R–8R.

25.

Flessner

Knight

. Prolongation of prothrombin time and severe gastrointestinal bleeding associated with combined use of warfarin and ketoprofen (letter). JAMA 1988;259:353.

26.

Gabb

. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug. Med J Aust 1996;164:700–1.

27.

Rhodes

Klein

Sintek

. A warfarin–piroxicam drug interaction. Drug Intell Clin Pharm 1985;19:556–8.

28.

Chan

. Prolongation of the prothrombin time with use of indomethacin and warfarin. Br J Clin Pharmacol 1997;51:177–8.

29.

Chan

. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother 1995;29:1274–83.

30.

Hallas

Lauritsen

Villadsen

Gram

. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438–44.

31.

O'laughlin

Hoftiezer

Ivey

. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand J Gastroenterol 1981;16(suppl 67): 211–4.

32.

Lanza

. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989;24(suppl 163): 24–31.

33.

Clinch

Banerjee

Ostick

. Absence of abdominal pain in elderly patients with peptic ulcer. Age Ageing 1984;13:120–3.

34.

Griffin

Piper

Daugherty

Snowden

Ray

. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257–63.

35.

Barrier

Hirschowitz

. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989;32:926–32.

36.

Eccles

Freemantle

Mason

. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998;317:526–30.

37.

Hochberg

Altman

Brandt

. Guidelines for the management of osteoarthritis. Arthritis Rheum 1995;38:1541–6.

38.

Batistella

Mamdani

Juurlink

Rabeneck

Lapaucis

. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005;165:189–92.

39.

Solomon

McMurray

Pfeffer

. Celecoxib increased cardiovascular events in patients with colorectal adenomas. N Engl J Med 2005;352:1071–80.

40.

Brophy

. Celecoxib and cardiovascular risks. Expert Opin Drug Saf 2005;4:1005–15.

41.

Jones

. Relative thromboembolic risks associated with COX-2 inhibitors. Ann Pharmacother 2005;39:1249–59. Epub 14 Jun 2005. DOI 10.1345/aph.1E654